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Objective: Previous tuberculosis (TB) treatment status
is an established risk factor for multidrug-resistant TB
(MDR-TB). This study explores which factors related to
previous TB treatment may lead to the development of
multidrug resistant in Bangladesh.
Design: We previously conducted a large case–
control study to identify risk factors for developing
MDR-TB in Bangladesh. Patients who had a history of
previous TB treatment, either MDR-TB or non-MDR-
TB, were interviewed about their previous treatment
episode. This study restricts analysis to the strata of
patients who have been previously treated for TB.
Information was collected through face-to-face
interviews and record reviews. Unadjusted and
multivariable logistic regression was used for data
analysis.
Setting: Central-level, district-level and
subdistrict-level hospitals in rural and urban
Bangladesh.
Results: The strata of previously treated patients
include a total of 293 patients (245 current MDR-TB;
48 non-MDR-TB). Overall, 54% of patients received
previous TB treatment more than once, and all of
these patients were multidrug resistant. Patients with
MDR-TB were more likely to have experienced the
following factors: incomplete treatment (OR 4.3; 95%
CI 1.7 to 10.6), adverse reactions due to TB treatment
(OR 8.2; 95% CI 3.2 to 20.7), hospitalisation for
symptoms associated with TB (OR 16.9; CI 1.8 to
156.2), DOTS (directly observed treatment, short-
course) centre as treatment unit (OR 6.4; CI 1.8 to
22.8), supervised treatment (OR 3.8; CI 1.6 to 9.5);
time-to-treatment centre (OR 0.984; CI 0.974 to
0.993).
Conclusions: Incomplete treatment, hospitalisation
for TB treatment and adverse reaction are the factors
related to previous TB treatment of patients with
MDR-TB. Although the presence of supervised
treatment (DOT), less time-to-treatment centres and
being treated in DOTS centres were relatively higher
among the patients with MDR-TB compared with
patients without MDR-TB, these findings include
information of their most recent TB treatment episode
only. Most (64.5%) of the patients with MDR-TB had
received TB treatment more than once.
INTRODUCTION
Global tuberculosis (TB) control efforts are
facing the additional challenge of multidrug-
resistant TB (MDR-TB).1 MDR-TB is caused
by bacteria that are resistant to at least isonia-
zid and rifampicin, the most effective anti-TB
drugs for treating TB.2 MDR-TB cannot be
treated with first-line anti-TB medicines and
needs a longer treatment period with stron-
ger second-line medicines.3 A total of 0.14
million cases of drug-resistant TB were
reported worldwide in 2013; however, the
estimate for MDR-TB incidence is at least
five times higher than the reported cases.4
The number of reported MDR-TB cases has
been increasing in recent years.4 Globally,
20.5% (13.6–27.5%) of previously treated
cases and 3.5% (2.2–4.7%) of new cases are
estimated to have MDR-TB.4 Previous TB
treatment is a known risk factor for
MDR-TB.5–11 Patients with previous TB treat-
ment are difficult to manage and might be
infectious for a longer period of time.
‘Previous treatment’ may mean a relapse
after a successful treatment, a return after
treatment discontinuation, a treatment
Strengths and limitations of this study
▪ Previous tuberculosis (TB) treatment is an
important risk factor for patients with multidrug-
resistant TB (MDR-TB). Information regarding
the previous TB treatment of MDR-TB is not
available in Bangladesh.
▪ Strata of previously treated patients have been
taken from a previously conducted large case–
control study with adequate sample size and
power.
▪ Information regarding the recent episode of the
previous TB treatment were collected to minimise
the recall bias. A majority of the patients with
MDR-TB were treated more than once but we do
not have information on other treatment episodes.
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failure, or any other types (other types include patients
with an unknown previous history; with unknown
outcome of that previous treatment; and/or who have
returned to treatment with smear-negative pulmonary
TB or bacteriologically negative extrapulmonary TB).12
Previously treated recurrent TB is no longer a neglected
area; rather, it is considered to be an important factor
for TB control.13 14 Programmatic factors such as poor
management of the patient, lack of directly observed
treatment, limited or interrupted drug supplies, poor
drug quality, widespread availability of anti-TB drugs
without prescription, lack of uniformity between the
public and private health sectors regarding the treat-
ment regimens, and poorly managed and supported
National TB Control Programmes (NTPs) were cited to
be the factors related to development of drug
resistance.15 16
The WHO has identified 27 high burden countries for
MDR-TB. Four of these countries, including Bangladesh,
belong to the South-East Asian region.17 In Bangladesh,
MDR-TB is an emerging public health problem.18
According to the recent drug-resistant survey (DRS),
1.4% of new cases and 29% of the retreatment cases in
Bangladesh have MDR-TB.19 Although the rate of
MDR-TB is still relatively low, owing to the overall high
TB burden in Bangladesh the absolute number of
MDR-TB cases was quite large, with 2100 among the
new patients with TB and 2600 among the previously
treated patients with TB, in 2013.4 Recent studies in
Bangladesh suggest that previous TB treatment is an
important risk factor for MDR-TB.19 20 Retreatment
patients constitute approximately 3% of all patients with
TB in the national data collection which corresponded
to 6385 patients in 2013.4 However, the detailed infor-
mation regarding the previous TB treatment has not yet
been collected. Factors related to previous management
of TB need to be identified to develop control strategies.
The main objective of this study is to explore the factors
related to the previous TB treatment of patients with
current MDR-TB compared with TB patients without
MDR-TB in Bangladesh.
METHODS
We previously conducted a case–control study to identify
the risk factors of MDR-TB in Bangladesh.21 The study
included 250 patients with MDR-TB and 750 TB patients
without MDR-TB, and the sample size demonstrated suf-
ficient power (80%) to detect at least a 10% difference
in the prevalence of any of the exposure variables at the
5% significance threshold.21 We found that 293 patients
(29.3%) (245 MDR-TB and 48 non-MDR-TB) had previ-
ously received treatment for TB. All patients with a
history of previous TB treatment were interviewed about
parameters related to their treatment history. This study
restricts analysis to the strata of patients who had previ-
ously received treatment for TB.
The setting, definition, and the inclusion and exclu-
sion criteria of the study have been previously described
in detail.21 The setting was central-level, district-level and
subdistrict-level hospitals in rural and urban Bangladesh.
Patients with MDR-TB aged between 18 and 65 years
who gave their informed consent were included in the
study. History of TB treatment and number of episodes
of previous TB treatment were based on the patient’s
statement. Patients, who received treatment for MDR-TB
following the diagnostic criteria of the NTP guidelines,
were classified as MDR-TB. The NTP has adopted auto-
mated real-time PCR (Xpert MTB/RIF) as the diagnos-
tic tool of patients with MDR-TB. Culture and
drug-sensitivity testing (DST) and line probe assays were
also used.22 Xpert MTB/RIF diagnoses only rifampicin
resistance. Patients who are resistant to rifampicin are
generally also resistant to isoniazid (another first-line
drug). Monoresistance to rifampicin is fairly uncommon
(0.2% and 0.4% among new and previously treated
patients, respectively), as shown by a recent DRS con-
ducted in Bangladesh.19 Patients with drug-susceptible
TB aged 18–65 years, who gave their informed consent,
were diagnosed through sputum smear microscopy or
other investigations (X-ray, fine-needle aspiration
cytology or biopsy) as per NTP guidelines and expected
to respond to the standard combination of drugs. In this
paper, we will refer to those as non-MDR-TB patients.
We excluded patients who were not within the eligible
age group or had any serious illness requiring admission
to the intensive care unit, recent surgery or any medical
emergency that needed continuous observation.
As the patients might have had more than one previ-
ous treatment episode, we collected detailed informa-
tion based on their most recent episode, to aid the
accuracy of the recalled information. According to the
national TB guidelines, the recommended duration of
TB treatment is 6 and 8 months for new and retreatment
types of drug-sensitive patients, respectively.23
The presence or absence of incomplete treatment
during the previous TB treatment was based on the
patient’s statement, which refers to any discontinuation
of treatment during the latest episode of previous TB
treatment. Treatment discontinuation due to treatment
failure is also included under ‘incomplete treatment’.
Data collection
TB patients with and without MDR-TB were identified as
part of a previously conducted case–control study on
risk factors of MDR-TB.21 Patients with MDR-TB from all
over Bangladesh are referred to one of the three govern-
ment hospitals, the national hospital in Dhaka or a
regional hospital in either Chittagong or Rajshahi. All
eligible patients with MDR-TB who were admitted from
September 2012 to mid-April 2013 were recruited from
these hospitals under the previously conducted study.
The hospitals that were providing MDR-TB treatment
were receiving patients referred by the various treatment
units from rural and urban Bangladesh. Each patient
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with TB is assigned a unique TB registration number as
a routine practice. Treatment registration numbers of
patients with TB, who were diagnosed during the speci-
fied period that is, during the same month that
MDR-TB was diagnosed, were listed. Three patients
without MDR-TB per patient with MDR-TB, from the
local TB treatment unit from where the case was
referred, were recruited under the previous study.
All patients who had a history of previous TB treat-
ment were subsequently interviewed about parameters
related to their previous treatment; these findings are
reported in this study. Site of previous treatment, treat-
ment regimen and treatment outcome-related informa-
tion were collected from the patient record review.
Trained investigators collected information from the
study participants by face-to-face interview using a pre-
tested questionnaire and by review of records. All the
investigators received training on data collection proce-
dures for one week. Diagnosis of TB through microscopy
is under an external quality assessment (EQA) network
at country level. The NTP has its inbuilt quality control
mechanism for diagnosis of patients with MDR-TB
through a laboratory based in Antwerp, Belgium.
Statistical analysis
We compared participant characteristics between
patients with (245) and without MDR-TB (48) using
Student t-tests for continuous measures, and χ2 tests for
categorical measures. Unadjusted and multivariable
logistic regression models were used to estimate ORs
(and 95% CIs) for MDR-TB status with the following
variables: site of previous TB, adverse reaction due to
TB treatment, hospitalisation due to TB, type of centre
for treatment initiation and follow-up, presence of super-
vised treatment (directly observed treatment, DOT),
time-to-treatment centre, incomplete treatment. We ini-
tially included all variables in the adjusted model, but
later excluded variables that had insufficient frequencies
or may have collinear relationships with the variables
included in the model. The excluded variables from the
multivariable model were: treatment regimen, treatment
outcome, treatment extension, type of provider, and
cost-to-treatment and distance-to-treatment centres.
Cost-to-treatment and distance-to-treatment centres were
excluded from the model for possible collinearity with
the variable ‘time-to-treatment centre’.
We assessed statistical significance of ORs using the
likelihood ratio tests, and we had sufficient patients to
include the variables in the multivariable model without
risk of overfitting. The ORs derived from these models
correspond to effects specific to the strata of patients
who have been previously treated for TB. Data analysis
was carried out using Stata statistical software V.12
(StataCorp LP).
Ethics considerations
An information sheet describing the purpose of the
study and the individuals’ rights as study participants was
handed to the participants to read. For individuals with
inadequate literacy, the information sheet was read out
by the interviewers. All participants consented by signing
the consent form or, if unable to do so, by adding their
thumb impression. All patients had been treated
through the NTP, Bangladesh.
RESULTS
Among the previously treated patients with MDR-TB,
64.5% had been treated more than once and all patients
without MDR-TB had only one episode of treatment pre-
viously. The mean age of previously treated patients with
MDR-TB was lower than that of patients without
MDR-TB. The majority of patients were male and had
pulmonary TB. Detailed demographic and clinical
characteristics are presented in table 1.
For some patients, it was not possible to get informa-
tion regarding the previous treatment outcome (19%),
treatment extension (9%) and previous treatment
regimen (11%) from the records. Among the patients
with MDR-TB, 63.7% received a retreatment regimen
commonly known as category 2, consisting of five drugs
including injectable streptomycin. On the basis of the
available records, all non-MDR-TB patients were treated
with the regimen for new patients with TB that consists
of a combination of four oral drugs. The most frequent
category for duration of previous treatment was
5 months (59.6%). The majority (64.6%) of patients
with drug-sensitive TB discontinued their treatment at
3 months or less. Treatment failure was higher among
the patients with MDR-TB compared with patients
without MDR-TB (68.4% and 28.6%, respectively)
during their previous treatment. Of the patients with
MDR-TB, 32.6% reported having an extended treatment
period since their sputum remained positive after the
intended period of treatment. This treatment extension
was only reported by 5.4% of the patients without
MDR-TB. Hospitalisation for TB-related problems
during their previous TB treatment mostly occurred for
patients with MDR-TB (13.5%). The three main causes
of hospitalisation during previous TB treatment were
massive haemoptysis (33.3%), severe weakness (33.3%)
and pleural effusion (15.2%) (these results are not
shown in table).
Patients were asked if they had stopped their treat-
ment at any point of their previous TB treatment, and
in this paper we refer to it as incomplete treatment.
Incomplete treatment during previous TB treatment was
reported by 63.3% and 29.2% of patients with and
without MDR-TB, respectively, as stated by the patients.
Reasons for incomplete treatment among the patients
with and without MDR-TB are presented in table 2.
Patients who do not complete their treatment are
supposed to be followed up by one of their healthcare
providers, according to the national TB guideline.23 A
high proportion (91.6%) of patients with MDR-TB
reported that they had been followed up during
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previous TB treatment, although follow-up was quite low
(14.3%) among patients without MDR-TB.
Patients with current MDR-TB had been treated for
their previous TB mostly in designated centres for TB
(DOTS (directly observed treatment strategy, short-
course) centre) (95.9%); for patients without MDR-TB,
the proportion was 70.8%. Rate of treatment in private
centres was 4.1% and 29.2% for patients with MDR-TB
and non-MDR-TB, respectively. Although the majority of
patients with MDR-TB were treated in DOTS centres,
supervised intake of medicine by DOT during their pre-
vious treatment was reported by 78.4% of patients with
MDR-TB and 41.7% of patients without MDR-TB,
respectively, as reported by the patients.
We further explored who had supervised the medi-
cine intake and found that 70.3% of patients with
MDR-TB and 80% of patients without MDR-TB were
given their medicine by trained providers (community
health volunteers, health workers at the facility or field
level, village doctors). The rest of the patients were
given their medicine by a family member, neighbours
or other providers.
The median travel time to visit the previous treatment
centre, which was the designated unit for treatment initi-
ation and follow-up, was 20 min for patients with
MDR-TB and 40min for patients without MDR-TB.
Details of health system factors are presented in table 3.
Logistic regression analysis
In the multivariable adjusted analysis, patients with
MDR-TB were shown to be more likely to be male (OR
5.1; CI 1.8 to 14), have a history of incomplete TB





(n=245) Total p Value
Age 0.0001*
Mean 41 33.8 35
SD 15.8 12.3 13.2
Age group (years) 0.002†
18–25 11 (22.9%) 79 (32.2%) 90 (30.7%)
26–45 17 (35.4%) 121 (49.4%) 138 (47.1%)
>45 20 (41.7%) 45 (18.4%) 65 (22.2%)
Sex 0.027†
Male 28 (58.3%) 163 (66.5%) 191 (65.2%)
Female 20 (41.7%) 82 (33.5%) 102 (34.8%)
Site of previous TB <0.0001†
Extrapulmonary 7 (14.6%) 5 (2.0%) 12 (4.1%)
Pulmonary 41 (85.4%) 240 (98.0%) 281 (95.9%)
Treatment regimen‡ <0.0001†
Category 1 16 (100%) 86 (35.1%) 102 (39.0%)
Category 2 0 (0%) 156 (63.7%) 156 (59.8%)
MDR-NTP 0 (0%) 2 (0.8%) 2 (0.8%)
Non-standardised 0 (0%) 1 (0.4%) 1 (0.0%)
Duration of treatment (months) <0.0001†
6–8 3 (6.3%) 15 (6.1%) 18 (6.1%)
4–5 14 (29.1%) 146 (59.6%) 160 (54.6%)
3 or less 31 (64.6%) 84 (34.3%) 115 (39.3%)
Treatment outcome‡ 0.001†
Cured 6 (42.8%) 20 (9.2%) 26 (11.2%)
Completed 4 (28.6%) 43 (19.7%) 47 (20.3%)
Default 0 (0%) 6 (2.8%) 6 (2.6%)
Failure 4 (28.6%) 149 (68.3%) 153 (65.9%)
Adverse reaction <0.0001†
Absent 34 (70.8%) 57 (23.3%) 91 (31.1%)
Present 14 (29.2%) 188 (76.7%) 202 (68.9%)
Treatment extension‡ 0.001†
Absent 35 (94.6%) 155 (67.4%) 190 (71.2%)
Present 2 (5.4%) 75 (32.6%) 77 (28.8%)
Hospitalisation due to TB 0.069†
Absent 46 (95.8%) 212 (86.5%) 258 (88.1%)
Present 2 (4.2%) 33 (13.5%) 35 (11.9%)
*Probability of Student t-test.
†Probability of χ2 test.
‡Treatment regimen, treatment outcome and treatment extension had a total of 261, 231 and 267 observations, respectively.
MDR-TB, multidrug-resistant tuberculosis; NTP, National TB Control Programme.
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treatment (OR 4.3; 95% CI 1.7 to 10.6), adverse reac-
tions due to anti-TB medicines (OR 8.2; 95% CI 3.2 to
20.7), hospitalisation due to TB (OR 16.9; CI 1.8 to
156.2), have been treated in a designated DOTS centre
(OR 6.4; CI 1.8 to 22.8) and time-to-treatment centre
(OR 0.984; CI 0.974 to 0.993).





n (%) p Value
Treatment completion <0.0001*
Completed treatment 34 (70.8) 90 (36.7)
Incomplete treatment 14 (29.2) 155 (63.3)
Reasons for incomplete treatment
Felt better 7 (50.0) 7 (4.5)
Remained positive in microscopy test 1 (7.1) 143 (92.3)
Change of address 4 (28.7) 0 (0)
Expense of treatment 1 (7.1) 1 (0.6)
Adverse effect 0 (0) 2 (1.3)
Lack of family support 1 (7.1) 0 (0)
Others 0 (0) 2 (1.3)
*Probability of χ2 test.
MDR-TB, multidrug-resistant tuberculosis.





n=245 Total p Value
Supervised treatment (DOT) <0.0001*
Unsupervised treatment 28 (58.3%) 53 (21.6%) 81 (27.6%)
Supervised treatment 20 (41.7%) 192 (78.4%) 212 (72.4%)
Type of DOT provider 0.36*
Trained provider† 16 (80%) 135 (70.3%) 151 (71.2%)
Family/other provider‡ 4 (20%) 57 (29.7%) 61 (28.8%)
Type of treatment unit <0.0001*
Private centre 14 (29.2%) 10 (4.1%) 24 (8.2%)
Designated DOTS centre 34 (70.8%) 235 (95.9%) 269 (91.8%)
Follow-up by the providers after incomplete treatment <0.0001*
No follow-up 12 (85.7%) 13 (8.4%) 25 (14.8%)
Follow-up done 2 (14.3%) 142 (91.6%) 144 (85.2%)
Time-to-treatment centre (min) 0.0005§
Mean 49.8 29.7 32.9
Median 40 20 30
SD 34.7 35.5 36.1
Range 5–150 1–420 1–420
Cost-to-treatment centre (BDT) 0.46§
Mean 27.3 22.9 23.6
Median 20 15 20
SD 22 38.3 36.1
Range 0–100 0–500 0–500
Distance-to-treatment centre (miles) 0.91§
Mean 4.6 4.3 4.3
Median 3 2 2
SD 4 16.1 14.9
Range 0.2–15 0–175 0–175
US$1 is 77 BDT approximately.
Time-to-treatment, cost-to-treatment and distance-to-treatment centres had a total of 286, 283 and 285 observations, respectively.
*Probability of χ2 test.
†Trained providers include providers trained on supervision on medicine intake (DOT) such as community health volunteers, health workers at
facility and field level and village doctors.
‡‘Family and other providers’ include family members, neighbours and other volunteers supervising the treatment.
§Probability of Student t-test.
BDT, Bangladesh taka; DOT, directly observed treatment; DOTS, DOT, short-course; MDR-TB, multidrug-resistant tuberculosis.
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Directly observed treatment (OR 3.8; 95% CI 1.6 to
9.5) was high among patients with MDR-TB during their
previous TB treatment compared to patients without
MDR-TB. Site of previous TB (pulmonary or extrapul-
monary) was no longer associated in the adjusted
model. Findings of the logistic regression are shown in
table 4.
DISCUSSION
Patients with MDR-TB were found to be four times more
likely to have a history of incomplete TB treatment
than patients without MDR-TB. Incomplete treatment
refers to discontinuation at any phase of the previous
treatment reported by patients. This finding has been
supported by many studies.5 10 24–26 The majority of
patients with MDR-TB (92.3%) stated that the reason for
incomplete treatment was that they remained positive to
TB bacteria in the microscopy test and had stopped
their previous treatment to initiate diagnosis and treat-
ment for MDR-TB. Remaining positive for TB bacteria is
an indication of treatment failure and thus ‘incomplete
treatment’ in this study also includes treatment failure.
This finding reflects the implementation of national
guidelines that recommend that the patients who do not
respond to the retreatment regimen should be referred
for diagnosis of MDR-TB.22 However, half of the patients
without MDR-TB did not complete their treatment as
they felt better after starting the treatment. The next
cause after ‘feeling better’ for treatment discontinuation
reported by patients without MDR-TB was change of
their address. Although the NTP has a system in place to
provide service to the patients transferred from one
place to another, these figures show that patient educa-
tion regarding discontinuation of treatment needs to be
further strengthened through advocacy communication
and social mobilisation activities.23 Although the patients
with MDR-TB reported that non-responsive previous
treatment was the main cause of their incomplete treat-
ment, these findings are based on their most recent
episode of previous treatment and most of the patients
with MDR-TB had more than one episode of earlier TB
treatment. The TB control programmes should address
the reasons for incomplete treatment for all types of
patients with TB. Incomplete treatment may lead to
development of drug resistance at any point of time irre-
spective of the number of treatment episodes.
Patients with MDR-TB were more likely to have
adverse reactions to anti-TB medication during their
previous TB treatment. Association of MDR-TB with
adverse reaction during their previous TB treatment was
found in another study and this association was
Table 4 Univariate and multivariable analyses on multidrug-resistant TB status and previous treatment-related factors
Univariate analysis Multivariable analysis
Variable OR 95% CI p Value* OR 95% CI p Value*
Age (years)
18–25 1 1
26–45 0.99 0.44 to 2.23 0.983 1.3 0.45 to 3.9 0.613
>45 0.31 0.14 to 0.71 0.006 0.33 0.10 to 1.12 0.075
Sex
Female 1 1
Male 1.4 2.5 to 6.7 0.277 5.1 1.8 to 14 0.002
Site of previous TB
Extrapulmonary 1 1
Pulmonary 8.2 2.5 to 27.1 0.001 2.6 0.52 to 13.1 0.244
Adverse effect
Absent 1 1
Present 8 4.0 to 16.0 <0.0001 8.2 3.2 to 20.7 <0.0001
Hospitalisation due to TB
Absent 1 1
Present 3.6 0.8 to 15.5 0.087 16.9 1.8 to 156.2 0.013
Supervised treatment (DOT)
Absent 1 1
Present 5.1 2.6 to 9.7 <0.0001 3.8 1.6 to 9.5 0.004
Type of treatment unit
Private 1 1
DOTS centre 9.7 4.0 to 23.5 <0.0001 6.4 1.8 to 22.8 0.004
Treatment completion
Completed treatment 1 1
Incomplete treatment 4.2 2.1 to 8.2 <0.0001 4.3 1.7 to 10.6 0.002
Time-to-treatment centre (min) 0.988 0.979 to 0.997 0.007 0.984 0.974 to 0.993 0.001
*Wald test statistic.
DOT, directly observed treatment; DOTS, directly observed treatment strategy; DOT, short-course; TB, tuberculosis.
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explained as the use of second-line drugs during their
previous TB treatment, and these are commonly more
toxic than first-line anti-TB drugs.27 In our study, we
found that most of the patients with MDR-TB were previ-
ously treated with retreatment regimens that did not
include any of the second-line drugs commonly used for
MDR-TB treatment. The retreatment regimen included
injectable streptomycin additional to the medicines used
for new patients. Additionally, adverse reaction as a
cause of incomplete treatment was reported by only
1.3% of patients with MDR-TB. However, the patients
with adverse reactions to anti-TB medicine can be
treated with special care. Patient education at the begin-
ning of treatment can be strengthened by advice on
adverse reactions.
Hospitalisation for more than 14 days associated with
MDR-TB and extensively drug-resistant TB (XDR-TB)
was found in one study.28 In our previous study, we did
not find any association of MDR-TB status with hospital-
isation due to any other cause within the past 7 months
of current treatment.21 Hospitalisation due to TB-related
causes during previous treatment was associated with
MDR-TB in our current study. This finding indicates that
patients may have experienced some difficulties and
complicated TB disease. Another possibility is that these
patients were not diagnosed properly as drug-resistant
patients, and became sick enough for hospitalisation
during their previous episode. The NTP may consider
MDR-TB testing for patients admitted to hospitals for
TB-specific problems. The recent national guideline
recommends that the following groups be tested for
MDR-TB: previously treated patients, patients with
current TB with treatment failure, patients with delayed
response in treatment or with smear-negative or extra-
pulmonary TB that does not improve clinically, patients
with relapse or who receive treatment after default,
patients who have HIV, and people in contact with
patients with MDR-TB.22
Camerino classified the risk factors for the emergence
of MDR-TB into two categories. The first category
includes some of the factors facilitating the selection of
resistance in the community and is closely linked to the
health system; it includes non-compliance, absence of
supervised treatment and the influence of private provi-
ders during previous treatment.7 The other category
includes factors that are related to the individual
patient’s vulnerability to develop MDR-TB, such as clin-
ical and demographic factors.7
In our study, more patients with MDR-TB reported
supervised treatment (DOT) during their most recent
TB treatment episode compared to patients without
MDR-TB (78.4% vs 41.7%). Absence of supervised treat-
ment may lead to irregular intake and cause drug resist-
ance, which is an established fact, but our finding looks
contradictory.29 However, this finding is based on the
most recent episode of previous TB treatment and we
do not have information on their other previous epi-
sodes, when they might have had irregular intake.
Moreover, during the latest episode of previous TB treat-
ment, the patients with MDR-TB might have been
treated with a retreatment regimen which contains
injectable streptomycin. Injection must be administered
by a provider and require more supervised care. This
could also explain the comparatively higher level of
follow-up among patients with MDR-TB by the providers
after incomplete treatment. We found that more patients
with than without MDR-TB reported being followed up
by a provider after treatment discontinuation during
their previous episode. Another possible explanation of
these findings could be that the health system approach
is targeted towards retreatment patients, as 63.7% of
patients with MDR-TB were receiving a retreatment
regimen (category 2) during their latest episode.
Retreatment regimens are complicated as patients have
a higher chance to develop MDR-TB and might have
taken more care compared with the patients who had
been treated on a new patient’s regimen (category 1).
However, patients with new TB require the same effort
as retreatment patients to prevent further development
of drug resistance.
The NTPs of high burden TB countries where a
private sector is also present face difficulties in imple-
menting treatment guidelines, resulting in inadequate
treatment or non-compliance.16 In Bangladesh, desig-
nated DOTS centres are the centres managed by public
and non-government organisations that are linked with
the NTP, which offers free services and medicine for TB
treatment. These DOTS centres are the point of treat-
ment initiation and follow-up. Private centres are for-
profit private practitioners, clinics and hospitals where
patients need to pay for TB treatment and these services
are not commonly linked with the TB control pro-
gramme. Medicines for TB are also available in the
private market in Bangladesh and the unregulated
private sector is likely to treat patients with TB using
non-standardised regimen, which may lead to the devel-
opment of drug resistance.30 In our study, patients with
MDR-TB had been enrolled mostly with the designated
DOTS centres during their most recent episode of previ-
ous TB, rather than private centres. The possible explan-
ation could be that retreatment patients are complicated
cases that private practitioners prefer not to treat. This
study is a hospital-based study and we assumed that most
of the patients with MDR-TB are treated at these three
government hospitals. We do not have any information
on patients with MDR-TB treated by private physicians
who are beyond NTP. However, we were not able to
collect information on other episodes to evaluate if
patients had been treated in the private sectors previ-
ously. Another study reported similar rates of MDR-TB
among patients treated by DOTS centres and by private
providers and thorough review of medication given
during previous treatment, regardless of its setting, was
recommended.31
The NTP of Bangladesh provides services integrated
into the basic health services.18 TB control through
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DOTS services has been expanded throughout the
country in all subdistricts and metropolitan cities with
the support of non-government organisations such as
BRAC, the Damien Foundation and other organisations
such as UPHCSDP, NHSDP and BGMEA, or through
public–private partnerships.18 Accessing services from
DOTS centres might reflect the expansion of DOTS ser-
vices and their reach of more patients. Widespread
deployment of community health workers and their
involvement in high-priority health areas including TB
has brought these services to the household level.32 The
community-based approach is adopted widely in
Bangladesh, so patients do not have to travel to health
centres for every administration of medicine; it can be
given by community-level providers and the patient only
visits the centre for diagnosis, follow-up and complica-
tions. Time-to-treatment centre was relatively lower (20
vs 40 min in MDR-TB and non-MDR-TB, respectively)
among the patients with MDR-TB compared with
patients without MDR-TB. We did not find any signifi-
cant difference in cost-to-treatment and distance-to-
treatment centres. Although access to treatment could
be a factor for developing drug resistance, we could not
make conclusions about this factor from our findings.
Patients may be living in closer proximities, along with
some other problems other than time, cost and distance,
to access the treatment. We also found that the second
major reason for incomplete treatment was change in
address which might be due to unstable living circum-
stances, such as the eviction of slum-dwellers in some
areas or losing a job. A detailed qualitative study needs
to be conducted in future regarding other treatment
access factors of patients with TB.
This study is a stratified analysis of all previously
treated TB patients with TB taken from a case–control
study which recruited patients with and without
MDR-TB representing the population. The sample size
and power were calculated on the basis of the initial risk
factor study, and as such our analysis of the subset has
less power than the full study, but the results still present
important exploratory findings. We do not have informa-
tion on all previous treatment episodes for the patients
as we had extracted the information on the basis of the
most recent episode, to aid the accuracy of the recalled
information. It was not feasible to confirm drug suscepti-
bility using DST of the patients with non-MDR-TB, as
only high-risk patients are routinely tested, and we did
not have the funds for this.
CONCLUSION
In conclusion, we found that incomplete treatment
which includes treatment discontinuation due to treat-
ment failure, adverse reactions to anti-TB medicine, and
hospitalisation for TB complications during previous TB
treatment are the main factors leading up to MDR-TB.
Although we found seemingly contradictory findings
regarding supervised treatment, less time required to
visit the treatment centre and the designated DOTS
centre, it does not necessarily mean that supervised
treatment, accessibility or being treated in a designated
DOTS centre contributes to MDR-TB. These findings
are based on the most recent episode of previous treat-
ment of patients with MDR-TB, as most patients have
more than one episode of previous TB treatment. In
addition, the health system may be better prepared for
the retreatment of patients. Therefore, basic DOTS ser-
vices should be strengthened for new patients to prevent
development of drug resistance. Patients who are hospi-
talised for TB-related causes could be tested for
MDR-TB. Patient education could be strengthened for
all patients with TB regarding adverse effect and
compliance-related issues.
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